Novo Nordisk Sues Over Semaglutide Copycats, Points to Serious Adverse Reactions

Novo Nordisk has sued nine more companies for selling products billed as containing semaglutide, a primary ingredient in the Danish pharma’s popular weight loss drug Wegovy.

The companies — that include medical spas, wellness clinics and pharmacies — join a list that now totals 21 lawsuits brought forward by Novo Nordisk, with five final judgements already entered by courts barring the defendants from misleading and unlawful marketing of compounded semaglutide drugs.

The lawsuits announced Thursday against the nine companies were filed in federal courts located in Colorado, Florida, Illinois, Montana, Tennessee and Texas.

To read the whole story, click here.

Related Topics